These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3326898)

  • 1. [Natural history of cancer of the prostate].
    Guiter J
    J Urol (Paris); 1987; 93(8):469-74. PubMed ID: 3326898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
    Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW
    Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis of prostate cancer with elevated prostatic acid phosphatase].
    Saito T; Kitamura Y; Komatsubara S
    Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate carcinoma--the value of T stage and grade in predicting metastases and prognosis. A cost-effective approach to clinical staging.
    Allen FJ; de Kock ML; de Klerk DP; Heyns CF
    S Afr J Surg; 1991 Mar; 29(1):15-8. PubMed ID: 1905062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Present status and questions on early prostatic cancer (stage A, B)].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1991 Aug; 37(8):789-93. PubMed ID: 1957722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of 169 patients with prostate cancer].
    Okaneya T; Mizusawa H; Yoneyama T; Taguchi I; Komiyama I; Kawakami M; Hosaka K; Tsuruta T; Murata Y; Komatsu H; Misawa K; Kiyokawa H
    Hinyokika Kiyo; 1996 Aug; 42(8):563-7. PubMed ID: 8889563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer.
    Griebling TL; Ozkutlu D; See WA; Cohen MB
    Mod Pathol; 1997 Aug; 10(8):804-9. PubMed ID: 9267823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extranodal extension in lymph node-positive prostate cancer.
    Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
    Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of clinical stage including extent of disease (EOD) in prostate cancer].
    Fujinami K; Kondo I; Miura T; Harada M; Uemura H; Hosaka M; Kawasaki C
    Hinyokika Kiyo; 1998 Apr; 44(4):259-63. PubMed ID: 9617622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiotherapy of localized prostatic carcinoma].
    Gez E; Netzer-Horowitz Y; Waiman E; Rubinov R; Cohen Y; Kuten A
    Harefuah; 1997 Dec; 133(12):593-6, 664. PubMed ID: 9451865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
    Lerner SE; Jacobsen SJ; Lilja H; Bergstralh EJ; Ransom J; Klee GG; Piironen T; Blute ML; Lieber MM; Zincke H; Pettersson K; Peterson D; Oesterling JE
    Urology; 1996 Aug; 48(2):240-8. PubMed ID: 8753736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.